You might also like
ZimVie Inc. is a medical technology company specializing in products that enhance the quality of life for dental and spine patients globally. The company designs, manufactures, and markets innovative solutions for dental tooth replacement and restoration procedures, as well as devices for treating spine pathologies. ZimVie operates through two primary product segments: Dental and Spine.
-
Dental - Develops and markets dental implant systems, biomaterials, and digital dentistry solutions for tooth replacement, restoration, and soft tissue and bone rehabilitation. Key products include T3® Implant, Tapered Screw-Vent® Implant System, Trabecular Metal® Dental Implant, BellaTek® Encode® Impression System, and Puros® Allograft Particulate.
-
Spine - Provides medical devices and surgical instruments for treating back or neck pain caused by degenerative conditions, deformities, or traumatic injuries. Notable products include Mobi-C® Cervical Disc, a motion-preserving alternative to fusion, and The Tether™, a non-fusion device for pediatric scoliosis.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Vafa Jamali ExecutiveBoard | Chief Executive Officer (CEO) | Vafa Jamali has been the CEO of ZimVie Inc. since February 2021 , and he also serves as President and Director since December 2021 and 2021 respectively. He will assume the role of Chairman of the Board effective May 7, 2025. | View Report → | |
Indraneel Kanaglekar Executive | Senior Vice President, Chief Commercial Officer | Indraneel Kanaglekar is the Senior Vice President, Chief Commercial Officer at ZimVie since April 2024. Previously, he served as Senior Vice President and President, Global Dental from June 2021 to April 2024. | ||
Richard Heppenstall Executive | Executive Vice President, Chief Financial Officer, and Treasurer | Richard Heppenstall has served as ZimVie's Executive Vice President, Chief Financial Officer, and Treasurer since September 2021, with his Treasurer role beginning in January 2022; he previously served as CFO at Breg, Inc. from April 2019 to September 2021. | ||
David King Board | Non-Executive Chair of the Board | Managing Member at Kingman LLC; Board member at Privia Health Group, Inc.; Board member at Emily K Center | David King has served as the Non-Executive Chair of the Board at ZimVie since its spinoff. He has been a board member since 2022 and participates in committees including Corporate Governance, Audit, Compensation, and Quality, Regulatory, and Technology. | |
Richard Kuntz Board | Director | DiaMedica Therapeutics Inc.; Identiv, Inc.; Bactiguard Holding AB | Richard Kuntz, M.D., M.Sc., has been serving as a Director at ZimVie Inc. since 2022 and is an active member of several board committees. He brings extensive expertise from his previous executive roles at Medtronic and academic institutions. | |
Vinit Asar Board | Director | Executive Chairman of the Board at Hanger, Inc.; Board Member at Veradigm Inc. | Vinit Asar has been a Director at ZimVie Inc. since 2022 and will serve as Lead Independent Director effective May 7, 2025. He serves on board committees including Audit, Compensation, Corporate Governance, and Quality, Regulatory, and Technology (Chair). |
- With your guidance for 2025 assuming a moderate market recovery in the back half of the year, particularly in the specialist-driven implant cases that haven't fully recovered yet, what specific indicators or trends give you confidence that this recovery will materialize, and what contingency plans do you have if it doesn't?
- Digital solutions excluding scanner sales grew over 20% in Q4 and over 10% for the year, but oral scanner sales continue to face pressure; what strategies are you implementing to address the declining scanner sales, and how do you plan to drive growth in this area?
- Your 2025 guidance relies on continued cost efficiencies and manufacturing improvements, resulting in adjusted EBITDA margin improvements despite declining revenues; how sustainable are these margin improvements without significant revenue growth, and what challenges do you foresee in maintaining or expanding margins if market conditions remain stagnant?
- You plan to in-source third-party work and transition more production to your Valencia facility, which currently offers 20% lower production costs; what risks are associated with this strategy, especially regarding quality control and capacity, and how will you ensure a smooth transition without disrupting operations?
- Biomaterials grew only 2% during the year, and the specialist volumes that drive significant growth haven't fully recovered; what specific steps are you taking to accelerate growth in your biomaterials segment, and how will you mitigate the impact if specialist volumes continue to lag?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The Straumann Group | The company competes primarily with this global medical technology company in the highly competitive and dynamic medical technology industry, which is affected by the introduction of new products and technologies and other market activities of industry participants. |
This company is one of the primary competitors in the global medical technology industry, which is characterized by rapid technological advancements and the introduction of new products. | |
Nobel Biocare Services AG (part of Envista Holdings Corporation) | As part of Envista Holdings Corporation, this company is a key competitor in the medical technology industry, which is subject to changes due to new product introductions and technological innovations. |
This company is a significant competitor in the medical technology sector, which is influenced by technological advancements and the introduction of new products and technologies. | |
Geistlich Pharma AG | This company is among the competitors in the medical technology industry, which is highly competitive and subject to change due to new product introductions and technological advancements. |
Recent press releases and 8-K filings for ZIMV.
- Deleveraging & Cost Reduction: Achieved a significant net debt reduction—from $437.3M in Q4 2023 to $145.5M in Q4 2024—and reduced net debt by more than $290M, underscoring strong financial discipline .
- Strategic Transformation: Completed the sale of its Spine business to become a pure-play dental company focused on dental implants, biomaterials, and digital dentistry, contributing to full-year 2024 revenue of approximately $450M .
- Robust Q4 2024 Performance: Recorded $111.5M in net sales, an improved net loss of $(9.7M) with margin tightening from 19.6% to 8.7%, alongside $18.4M in Adjusted EBITDA (up 32%) and over $21M in operating cash flow .
- Full-Year 2024 Results: Reported third party net sales of $449.7M, a net loss of $(33.8M), and adjusted diluted EPS of $0.62, highlighting operational improvements .
- FY 2025 Guidance: Projects revenue between $445M–$460M and Adjusted EBITDA of $65M–$70M, setting the stage for further margin expansion and a path to positive GAAP operating income .